{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T14:30:43Z","timestamp":1794666643295,"version":"4.9.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"DOI":"10.1186\/s13063-025-08901-y","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T14:20:26Z","timestamp":1750515626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The effect of Colchicine IN Sepsis (COLINS): a study protocol for a randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Fariba","family":"Pourkarim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ata","family":"Mahmoodpoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Soleimanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliakbar","family":"Ghamari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roghayeh","family":"Asghari-Ardabili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvin","family":"Sarbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Hamishehkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"issue":"6","key":"8901_CR1","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","volume":"101","author":"RC Bone","year":"1992","unstructured":"Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644\u201355. https:\/\/doi.org\/10.1378\/chest.101.6.1644.","journal-title":"Chest"},{"issue":"8","key":"8901_CR2","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","journal-title":"JAMA"},{"issue":"10","key":"8901_CR3","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1097\/00003246-200010000-00005","volume":"28","author":"JA Russell","year":"2000","unstructured":"Russell JA, Singer J, Bernard GR, Wheeler A, Fulkerson W, Hudson L, et al. Changing pattern of organ dysfunction in early human sepsis is related to mortality. Crit Care Med. 2000;28(10):3405\u201311. https:\/\/doi.org\/10.1097\/00003246-200010000-00005.","journal-title":"Crit Care Med"},{"issue":"2","key":"8901_CR4","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1164\/rccm.2201087","volume":"168","author":"D Annane","year":"2003","unstructured":"Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med. 2003;168(2):165\u201372. https:\/\/doi.org\/10.1164\/rccm.2201087.","journal-title":"Am J Respir Crit Care Med"},{"issue":"16","key":"8901_CR5","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1056\/NEJMoa022139","volume":"348","author":"GS Martin","year":"2003","unstructured":"Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348(16):1546\u201354. https:\/\/doi.org\/10.1056\/NEJMoa022139.","journal-title":"N Engl J Med"},{"issue":"9","key":"8901_CR6","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1056\/NEJMra1208623","volume":"369","author":"DC Angus","year":"2013","unstructured":"Angus DC, Van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369(9):840\u201351. https:\/\/doi.org\/10.1056\/NEJMra1208623.","journal-title":"N Engl J Med"},{"issue":"23","key":"8901_CR7","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJM199906103402312","volume":"340","author":"RL Modlin","year":"1999","unstructured":"Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. N Engl J Med. 1999;340(23):1834\u20135. https:\/\/doi.org\/10.1056\/NEJM199906103402312.","journal-title":"N Engl J Med"},{"issue":"2","key":"8901_CR8","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.2741\/1304","volume":"9","author":"MA Brown","year":"2004","unstructured":"Brown MA, Jones WK. NF-\u03baB action in sepsis: the innate immune system and the heart. Front Biosci. 2004;9(2):1201\u201317. https:\/\/doi.org\/10.2741\/1304.","journal-title":"Front Biosci"},{"issue":"16","key":"8901_CR9","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1056\/NEJMra043632","volume":"355","author":"JA Russell","year":"2006","unstructured":"Russell JA. Management of sepsis. N Engl J Med. 2006;355(16):1699\u2013713. https:\/\/doi.org\/10.1056\/NEJMra043632.","journal-title":"N Engl J Med"},{"issue":"7","key":"8901_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1517\/13543784.9.7.1651","volume":"9","author":"BD Freeman","year":"2000","unstructured":"Freeman BD, Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs. 2000;9(7):1651\u201363. https:\/\/doi.org\/10.1517\/13543784.9.7.1651.","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"8901_CR11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1001\/archsurg.133.1.94","volume":"133","author":"KH Staubach","year":"1998","unstructured":"Staubach KH, Schr\u00f6der J, St\u00fcber F, Gehrke K, Traumann E, Zabel P. Effect of pentoxifylline in severe sepsis: results of a randomized, double-blind, placebo-controlled study. Arch Surg. 1998;133(1):94\u2013100. https:\/\/doi.org\/10.1001\/archsurg.133.1.94.","journal-title":"Arch Surg"},{"issue":"9508","key":"8901_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(06)68041-0","volume":"367","author":"DG Hackam","year":"2006","unstructured":"Hackam DG, Mamdani M, Li P, Redelmeier DA. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet. 2006;367(9508):413\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(06)68041-0.","journal-title":"Lancet"},{"issue":"4","key":"8901_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1056\/NEJM199207233270404","volume":"327","author":"A Cometta","year":"1992","unstructured":"Intravenous Immunoglobulin Collaborative Study Group, Cometta A, Baumgartner J-D, Lee ML, Hanique G, Glauser M-P. Prophylactic intravenous administration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infection. N Engl J Med. 1992;327(4):234\u201340. https:\/\/doi.org\/10.1056\/NEJM199207233270404.","journal-title":"N Engl J Med."},{"issue":"13","key":"8901_CR14","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1056\/NEJM199703273361303","volume":"336","author":"GR Bernard","year":"1997","unstructured":"Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 1997;336(13):912\u20138. https:\/\/doi.org\/10.1056\/NEJM199703273361303.","journal-title":"N Engl J Med."},{"issue":"3","key":"8901_CR15","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s00011-022-01540-y","volume":"71","author":"A Bonaventura","year":"2022","unstructured":"Bonaventura A, Vecchi\u00e9 A, Dagna L, Tangianu F, Abbate A, Dentali F. Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation. Inflamm Res. 2022;71(3):293\u2013307. https:\/\/doi.org\/10.1007\/s00011-022-01540-y.","journal-title":"Inflamm Res"},{"issue":"1","key":"8901_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7861\/clinmed.cme.20.1.4","volume":"20","author":"TF Ismail","year":"2020","unstructured":"Ismail TF. Acute pericarditis: update on diagnosis and management. Clin Med (Lond). 2020;20(1):48\u201351. https:\/\/doi.org\/10.7861\/clinmed.cme.20.1.4.","journal-title":"Clin Med (Lond)"},{"issue":"9","key":"8901_CR17","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1016\/S2665-9913(23)00165-0","volume":"5","author":"T Pascart","year":"2023","unstructured":"Pascart T, Robinet P, Ottaviani S, Leroy R, Segaud N, Pacaud A, et al. Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial. Lancet Rheumatol. 2023;5(9):e523\u201331. https:\/\/doi.org\/10.1016\/S2665-9913(23)00165-0.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"8901_CR18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.semarthrit.2020.10.005","volume":"51","author":"K Parperis","year":"2021","unstructured":"Parperis K, Papachristodoulou E, Kakoullis L, Rosenthal AK. Management of calcium pyrophosphate crystal deposition disease: a systematic review. Semin Arthritis Rheum. 2021;51(1):84\u201394. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.10.005.","journal-title":"Semin Arthritis Rheum"},{"key":"8901_CR19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1750-1172-2-34","volume":"2","author":"PR Cohen","year":"2007","unstructured":"Cohen PR. Sweet\u2019s syndrome\u2013a comprehensive review of an acute febrile neutrophilic dermatosis. Orphanet J Rare Dis. 2007;2:34. https:\/\/doi.org\/10.1186\/1750-1172-2-34.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"8901_CR20","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1046\/j.1365-2133.1999.02747.x","volume":"140","author":"H Maillard","year":"1999","unstructured":"Maillard H, Leclech C, Peria P, Avenel-Audran M, Verret JL. Colchicine for Sweet\u2019s syndrome. A study of 20 cases. Br J Dermatol. 1999;140(3):565\u20136. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02747.x.","journal-title":"Br J Dermatol."},{"issue":"3","key":"8901_CR21","doi-asserted-by":"publisher","first-page":"104033","DOI":"10.1016\/j.lpm.2020.104033","volume":"49","author":"RG Micheletti","year":"2020","unstructured":"Micheletti RG, Pagnoux C. Management of cutaneous vasculitis. Presse Med. 2020;49(3):104033. https:\/\/doi.org\/10.1016\/j.lpm.2020.104033.","journal-title":"Presse Med"},{"issue":"5","key":"8901_CR22","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.clindermatol.2006.07.007","volume":"24","author":"JA Carlson","year":"2006","unstructured":"Carlson JA, Cavaliere LF, Grant-Kels JM. Cutaneous vasculitis: diagnosis and management. Clin Dermatol. 2006;24(5):414\u201329. https:\/\/doi.org\/10.1016\/j.clindermatol.2006.07.007.","journal-title":"Clin Dermatol"},{"issue":"1","key":"8901_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/s13098-024-01369-x","volume":"16","author":"J Guan","year":"2024","unstructured":"Guan J, Abudouaini H, Lin K, Yang K. Emerging insights into the role of IL-1 inhibitors and colchicine for inflammation control in type 2 diabetes. Diabetol Metab Syndr. 2024;16(1):140. https:\/\/doi.org\/10.1186\/s13098-024-01369-x.","journal-title":"Diabetol Metab Syndr"},{"issue":"3","key":"8901_CR24","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s10753-023-01783-9","volume":"46","author":"A Kenig","year":"2023","unstructured":"Kenig A, Keidar-Haran T, Azmanov H, Kessler A, Kolben Y, Tayri-Wilk T, et al. Low-dose colchicine attenuates sepsis-induced liver injury: a novel method for alleviating systemic inflammation. Inflammation. 2023;46(3):963\u201374. https:\/\/doi.org\/10.1007\/s10753-023-01783-9.","journal-title":"Inflammation"},{"issue":"4","key":"8901_CR25","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1007\/s10787-023-01199-9","volume":"31","author":"Y Liu","year":"2023","unstructured":"Liu Y, Yang H, Zhu F, Ouyang Y, Pan P. Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury. Inflammopharmacology. 2023;31(4):2007\u201321. https:\/\/doi.org\/10.1007\/s10787-023-01199-9.","journal-title":"Inflammopharmacology"},{"issue":"3","key":"8901_CR26","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan AW, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137. https:\/\/doi.org\/10.7326\/0003-4819-158-3-201302050-00583.","journal-title":"Ann Intern Med"},{"key":"8901_CR27","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.eujim.2020.101122","volume":"36","author":"A Karimi","year":"2020","unstructured":"Karimi A, Mahmoodpoor A, Kooshki F, Niazkar HR, Shoorei H, Tarighat-Esfanjani A. Effects of nanocurcumin on inflammatory factors and clinical outcomes in critically ill patients with sepsis: a pilot randomized clinical trial. Eur J Integr Med. 2020;36:101122. https:\/\/doi.org\/10.1016\/j.eujim.2020.101122.","journal-title":"Eur J Integr Med"},{"issue":"2","key":"8901_CR28","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jcrc.2005.04.005","volume":"20","author":"GS Doig","year":"2005","unstructured":"Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005;20(2):187\u201391. https:\/\/doi.org\/10.1016\/j.jcrc.2005.04.005. discussion 91\u20133.","journal-title":"J Crit Care."},{"issue":"7","key":"8901_CR29","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00134-018-5197-6","volume":"44","author":"SL Ryg\u00e5rd","year":"2018","unstructured":"Ryg\u00e5rd SL, Butler E, Granholm A, M\u00f8ller MH, Cohen J, Finfer S, et al. Low-dose corticosteroids for adult patients with septic shock: a systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2018;44(7):1003\u201316. https:\/\/doi.org\/10.1007\/s00134-018-5197-6.","journal-title":"Intensive Care Med"},{"issue":"11","key":"8901_CR30","doi-asserted-by":"publisher","first-page":"e1063","DOI":"10.1097\/CCM.0000000000005337","volume":"49","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Crit Care Med. 2021;49(11):e1063\u2013143. https:\/\/doi.org\/10.1097\/CCM.0000000000005337.","journal-title":"Crit Care Med"},{"issue":"9","key":"8901_CR31","doi-asserted-by":"publisher","first-page":"CD001090","DOI":"10.1002\/14651858.CD001090.pub2","volume":"2013","author":"MM Alejandria","year":"2013","unstructured":"Alejandria MM, Lansang MA, Dans LF, Mantaring JB 3rd. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013;2013(9):CD001090. https:\/\/doi.org\/10.1002\/14651858.CD001090.pub2.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"8901_CR32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1086\/421089","volume":"39","author":"J Pildal","year":"2004","unstructured":"Pildal J, G\u00f8tzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis. 2004;39(1):38\u201346. https:\/\/doi.org\/10.1086\/421089.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"8901_CR33","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1097\/01.CCM.0000295263.12774.97","volume":"35","author":"KG Kreymann","year":"2007","unstructured":"Kreymann KG, de Heer G, Nierhaus A, Kluge S. Use of polyclonal immunoglobulins as adjunctive therapy for sepsis or septic shock. Crit Care Med. 2007;35(12):2677\u201385. https:\/\/doi.org\/10.1097\/01.CCM.0000295263.12774.97.","journal-title":"Crit Care Med"},{"issue":"12","key":"8901_CR34","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1097\/01.ccm.0000295312.13466.1c","volume":"35","author":"KB Laupland","year":"2007","unstructured":"Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immunoglobulin for the treatment of severe sepsis and septic shock in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2007;35(12):2686\u201392. https:\/\/doi.org\/10.1097\/01.ccm.0000295312.13466.1c.","journal-title":"Crit Care Med"},{"issue":"12","key":"8901_CR35","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1097\/01.CCM.0000295277.26957.65","volume":"35","author":"EA Neugebauer","year":"2007","unstructured":"Neugebauer EA. To use or not to use? Polyclonal intravenous immunoglobulins for the treatment of sepsis and septic shock. Crit Care Med. 2007;35(12):2855\u20136. https:\/\/doi.org\/10.1097\/01.CCM.0000295277.26957.65.","journal-title":"Crit Care Med"},{"issue":"1","key":"8901_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/00024382-199801000-00002","volume":"9","author":"S Kleinschmidt","year":"1998","unstructured":"Kleinschmidt S, Wanner GA, Bussmann D, Kremer JP, Ziegenfuss T, Menger MD, et al. Proinflammatory cytokine gene expression in whole blood from patients undergoing coronary artery bypass surgery and its modulation by pentoxifylline. Shock. 1998;9(1):12\u201320. https:\/\/doi.org\/10.1097\/00024382-199801000-00002.","journal-title":"Shock"},{"issue":"16","key":"8901_CR37","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1001\/jama.2013.280031","volume":"310","author":"L Papazian","year":"2013","unstructured":"Papazian L, Roch A, Charles PE, Penot-Ragon C, Perrin G, Roulier P, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA. 2013;310(16):1692\u2013700. https:\/\/doi.org\/10.1001\/jama.2013.280031.","journal-title":"JAMA"},{"issue":"4","key":"8901_CR38","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1097\/01.CCM.0000207345.92928.E4","volume":"34","author":"RW Thomsen","year":"2006","unstructured":"Thomsen RW, Hundborg HH, Johnsen SP, Pedersen L, S\u00f8rensen HT, Sch\u00f8nheyder HC, et al. Statin use and mortality within 180 days after bacteremia: a population-based cohort study. Crit Care Med. 2006;34(4):1080\u20136. https:\/\/doi.org\/10.1097\/01.CCM.0000207345.92928.E4.","journal-title":"Crit Care Med"},{"issue":"9508","key":"8901_CR39","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/S0140-6736(06)68042-2","volume":"367","author":"MW Merx","year":"2006","unstructured":"Merx MW, Weber C. Statins: a preventive strike against sepsis in patients with cardiovascular disease? Lancet. 2006;367(9508):372\u20133. https:\/\/doi.org\/10.1016\/S0140-6736(06)68042-2.","journal-title":"Lancet"},{"issue":"7576","key":"8901_CR40","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1136\/bmj.38992.565972.7C","volume":"333","author":"SR Majumdar","year":"2006","unstructured":"Majumdar SR, McAlister FA, Eurich DT, Padwal RS, Marrie TJ. Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study. BMJ. 2006;333(7576):999. https:\/\/doi.org\/10.1136\/bmj.38992.565972.7C.","journal-title":"BMJ"},{"issue":"6","key":"8901_CR41","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1164\/rccm.201006-0955OC","volume":"183","author":"PS Kruger","year":"2011","unstructured":"Kruger PS, Harward ML, Jones MA, Joyce CJ, Kostner KM, Roberts MS, et al. Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med. 2011;183(6):774\u201381. https:\/\/doi.org\/10.1164\/rccm.201006-0955OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"8901_CR42","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1097\/CCM.0b013e31821b8290","volume":"39","author":"S Yende","year":"2011","unstructured":"Yende S, Milbrandt EB, Kellum JA, Kong L, Delude RL, Weissfeld LA, et al. Understanding the potential role of statins in pneumonia and sepsis. Crit Care Med. 2011;39(8):1871\u20138. https:\/\/doi.org\/10.1097\/CCM.0b013e31821b8290.","journal-title":"Crit Care Med"},{"issue":"8","key":"8901_CR43","first-page":"921","volume":"81","author":"G Thomas","year":"2015","unstructured":"Thomas G, Hraiech S, Loundou A, Truwit J, Kruger P, Mcauley DF, et al. Statin therapy in critically-ill patients with severe sepsis: a review and meta-analysis of randomized clinical trials. Minerva Anestesiol. 2015;81(8):921\u201330.","journal-title":"Minerva Anestesiol"},{"issue":"4","key":"8901_CR44","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.amjmed.2014.10.057","volume":"128","author":"A Deshpande","year":"2015","unstructured":"Deshpande A, Pasupuleti V, Rothberg MB. Statin therapy and mortality from sepsis: a meta-analysis of randomized trials. Am J Med. 2015;128(4):410-7.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2014.10.057.","journal-title":"Am J Med"},{"issue":"6","key":"8901_CR45","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jama.1997.03540300050033","volume":"277","author":"AM Fein","year":"1997","unstructured":"Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr, Knaus WA, et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA. 1997;277(6):482\u20137. https:\/\/doi.org\/10.1001\/jama.1997.03540300050033.","journal-title":"JAMA."},{"key":"8901_CR46","doi-asserted-by":"publisher","first-page":"106322","DOI":"10.1016\/j.rmed.2021.106322","volume":"178","author":"A Vitiello","year":"2021","unstructured":"Vitiello A, Ferrara F. Colchicine and SARS-CoV-2: management of the hyperinflammatory state. Respir Med. 2021;178:106322. https:\/\/doi.org\/10.1016\/j.rmed.2021.106322.","journal-title":"Respir Med"},{"issue":"10","key":"8901_CR47","doi-asserted-by":"publisher","first-page":"e20155","DOI":"10.1016\/j.heliyon.2023.e20155","volume":"9","author":"MI Danjuma","year":"2023","unstructured":"Danjuma MI, Sayed R, Aboughalia M, Hassona A, Elsayed BS, Elshafei M, et al. Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses. Heliyon. 2023;9(10):e20155. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20155.","journal-title":"Heliyon"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-08901-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-08901-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T14:20:27Z","timestamp":1750515627000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-08901-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8901"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-08901-y","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"25 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Research Ethics Committee of Tabriz University of Medical Sciences, Tabriz, Iran (IR.TBZMED.PHARMACY.REC.1402.002), and then registered in  with the clinical trial ID of IRCT20231017059748 N1. The research protocol is designed under the Declaration of Helsinki and later revisions of ethical principles for medical research. All respective institutional review boards and regulatory authorities reviewed and approved the protocol before registration. The researchers will explain the trial protocol and any related modifications in detail to patients, their trustees, or their guardians. At the beginning of the study, a modified version of the World Health Organization\u2019s (WHO) informed consent form template will be used to obtain written informed consent for participation by HH. Ethical consent forms will be completed for all participants before the study. Also, consent for participants\u2019 biological specimen collection will be obtained for the quantification of procalcitonin and IL-6 serum levels.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent participate"}},{"value":"There will be no personal identifying information published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}